Vantis Vascular Receives FDA Clearance for CrossFAST System
Vantis Vascular, a pioneering medical technology firm founded with the aim of revolutionizing vascular interventions, has recently made a notable advancement. The company has announced that it has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative CrossFAST Integrated Microcatheter Guide Extension System. This system is tailored to assist physicians in performing vascular procedures in a way that is faster, easier, and significantly safer.
Revolutionizing Vascular Interventions
At Vantis, their primary goal is to transform the navigation of complex and tortuous anatomy within vascular procedures. Dr. Tim Fischell, Chief Medical Officer at Vantis, emphasized the current demand for improved guide extension catheters that can tackle anatomical challenges effectively. As the number of complex, high-risk patients increases within the healthcare landscape, the need for advanced solutions is paramount. The CrossFAST System is designed to enhance deliverability, thereby potentially revolutionizing physician practices in reaching target locations.
Benefits of CrossFAST Technology
The importance of guide extension catheters cannot be overstated in the realm of vascular interventions. They provide essential support and enable the delivery of devices in complex, high-risk scenarios. Traditionally, guide extension catheters suffer from limitations such as inadequate pushability and the associated risk of vessel trauma during the delivery process. In contrast, the CrossFAST Guide Extension System leverages patented DuoPro™ Interlocking Technology. This groundbreaking mechanism unites the outer and inner extension catheters to enhance safety and deliverability throughout the entire interventional process.
A Commitment to Patient Safety
Vantis Vascular is enthusiastic about receiving FDA clearance for this innovative guide extension system, which they see as a pivotal development in reshaping how physicians address complex anatomical challenges. Jason Turner, the Chief Executive Officer, highlighted that the company has put significant effort into crafting a solution that not only enhances the capabilities of interventional cardiologists but also prioritizes the safety of patients. The CrossFAST System is a testament to Vantis's commitment to addressing the genuine challenges that healthcare providers encounter in complex interventions.
Commercial Availability and Future Plans
The CrossFAST Guide Extension System is set to become commercially available in the United States during the later part of 2024 as a limited market release. An extensive market release is on the horizon for 2025, reflecting Vantis's forward-thinking approach to expanding the accessibility of their groundbreaking technology.
About Vantis Vascular
Vantis Vascular, Inc. is at the forefront of the medical technology sector, focusing on redefining vascular interventions. Founded by dedicated physicians, Vantis designs performance-driven technologies aimed at delivering faster, safer, and more effective patient treatments. With a pronounced focus on innovation and patient-centered solutions, Vantis is committed to advancing the fields of interventional cardiology and improving patient outcomes globally.
Frequently Asked Questions
What is the CrossFAST System?
The CrossFAST System is an integrated microcatheter guide extension system designed to improve the delivery of devices in vascular interventions.
Who received the FDA clearance?
Vantis Vascular, a medical technology company, received FDA clearance for the CrossFAST System.
When will the CrossFAST System be available?
The system is expected to be commercially available in the United States in the fourth quarter of 2024.
What is Vantis Vascular's mission?
Vantis aims to revolutionize vascular interventions by creating advanced medical technologies that enhance patient safety and treatment effectiveness.
How does the CrossFAST System enhance safety in procedures?
The CrossFAST System utilizes DuoPro™ Interlocking Technology, which improves deliverability and reduces risks associated with traditional guide extension catheters.
